Success Metrics

Clinical Success Rate
78.0%

Based on 46 completed trials

Completion Rate
78%(46/59)
Active Trials
1(2%)
Results Posted
76%(35 trials)
Terminated
13(20%)

Phase Distribution

Ph phase_4
3
5%
Ph phase_2
32
49%
Ph early_phase_1
1
2%
Ph not_applicable
4
6%
Ph phase_3
6
9%
Ph phase_1
14
22%

Phase Distribution

15

Early Stage

32

Mid Stage

9

Late Stage

Phase Distribution60 total trials
Early Phase 1First-in-human
1(1.7%)
Phase 1Safety & dosage
14(23.3%)
Phase 2Efficacy & side effects
32(53.3%)
Phase 3Large-scale testing
6(10.0%)
Phase 4Post-market surveillance
3(5.0%)
N/ANon-phased studies
4(6.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.7%

46 of 60 finished

Non-Completion Rate

23.3%

14 ended early

Currently Active

1

trials recruiting

Total Trials

65

all time

Status Distribution
Active(1)
Completed(46)
Terminated(14)
Other(4)

Detailed Status

Completed46
Terminated13
unknown4
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
65
Active
1
Success Rate
78.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.7%)
Phase 114 (23.3%)
Phase 232 (53.3%)
Phase 36 (10.0%)
Phase 43 (5.0%)
N/A4 (6.7%)

Trials by Status

unknown46%
recruiting12%
withdrawn12%
terminated1320%
completed4671%

Recent Activity

Clinical Trials (65)

Showing 20 of 65 trialsScroll for more
NCT03390673Phase 1

To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects

Completed
NCT07527832

An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.

Completed
NCT05745857Phase 2

Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

Recruiting
NCT05446870Phase 2

Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

Completed
NCT03676192Phase 3

To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

Completed
NCT05571267Phase 2

Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

Terminated
NCT06232902Phase 1

A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers

Completed
NCT05318443Phase 3

A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer

Completed
NCT02843230

Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI

Completed
NCT05110118Phase 1

Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects

Completed
NCT00723125Phase 2

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

Completed
NCT00652119Phase 1

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

Unknown
NCT02272413Phase 3

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

Completed
NCT01972490Phase 4

Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Completed
NCT02776683Phase 3

Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer

Completed
NCT00240071Phase 2

Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.

Completed
NCT01170767Phase 3

French Evaluation Group Avastin Versus Lucentis

Completed
NCT01186406Phase 2

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

Terminated
NCT03659305Phase 1

Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®

Completed
NCT02348918Phase 2

Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema

Completed

Drug Details

Intervention Type
DRUG
Total Trials
65